Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Globe Newswire•29/10/2026•09:00 ET
0
Key Highlights
- ➤Immunocore will present Phase 1/2 brenetafusp data with KIMMTRAK in metastatic uveal melanoma
- ➤Additional safety and efficacy data will be presented at SITC on November 6-7, 2026
- ➤Combination is described as the first two-T-cell-engager regimen evaluated in a solid tumor
- ➤KIMMTRAK is approved for HLA-A*02:01-positive unresectable or metastatic uveal melanoma in 39 countries
- ➤KIMMTRAK cytokine release syndrome occurred in 89% of patients, including 0.8% grade 3 or 4
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK(®) (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, November 6, and an oral presentation on November 7
Get started
Create a free account to read the full story.